Fresenius Medical Care AG & Co. KGaA (0H9X) Price & Analysis
0H9X Stock Chart & Stats
- Day’s Range
- EUR 40.39 - EUR 41.10
- 52-Week Range
- EUR 34.60 - EUR 46.82
- Previous Close
- EUR 41.42
- Volume
- 32.07K
- Average Volume (3M)
- 143.65K
- Market Cap
- EUR 10.73B
- Enterprise Value
- EUR 21.51B
- Total Cash (Recent Filing)
- EUR 1.45B
- Total Debt (Recent Filing)
- EUR 10.96B
- Price to Earnings (P/E)
- 12.2
- Beta
- 0.44
- Next Earnings
- Nov 03, 2026
- EPS Estimate
- 1.14
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.69%
Bulls Say, Bears Say
Bulls Say
Recurring Integrated Demand
Dialysis treatments require multiple sessions each week, while consumables are needed for each session; combining clinics with products therefore creates recurring demand across internal and external customers. This integrated base can support durable revenue visibility over the next several quarters.
Improving Operating Performance
TTM revenue growth of 35.8% alongside EBIT margin expansion to about 10.8% from 6.8% in 2023 indicates meaningful improvement in both scale and operating efficiency. If sustained, this combination can strengthen earnings capacity and provide more resources for investment.
Solid Cash Generation
TTM operating cash flow of about 2.83B and free cash flow of 1.78B demonstrate substantial cash generation from the operating base. Consistent conversion supports ongoing investment and financial commitments, even though the latest growth rate was modestly softer.
Bears Say
Mid-level Net Profitability
Net margin of about 4.8% remains only mid-level and has been roughly flat versus 2025, while margins have varied across years. This leaves less earnings protection if operating conditions become less favorable over the medium term.
Reduced Equity Cushion
Equity has declined from 2022–2024 highs to TTM levels, reducing the balance-sheet cushion even as debt-to-equity improved to about 0.83. A smaller equity base can limit resilience and flexibility if profitability weakens or funding needs increase.
Softer Free-cash-flow Momentum
Free cash flow growth was slightly negative at -3.6% in TTM after a modest increase in 2025. Although cash generation remains solid, this reversal signals softer recent momentum and could constrain the pace at which internally generated funds support expansion or distributions.
Fresenius Medical Care AG & Co. KGaA News
0H9X FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Is Fresenius Medical Care AG & Co. KGaA overvalued?
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
What is the TipRanks Smart Score and how is it calculated?
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
- Sector
- General
- Industry
- Medical - Care Facilities
- CEO
- Helen Giza
- Employees
- 107,226
- Website
- www.freseniusmedicalcare.com
- Address
- Else-KrOener Strasse 1, Bad Homburg, HE, 61352, DE
Fresenius Medical Care AG & Co. KGaA (0H9X) Earnings & Revenues
0H9X Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 6 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 9 | 0 | 3 |